glp 1 agonists contraindications Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning GLP-1 Receptor Agonists as Treatments

In type-2 diabetic models (genetically-inherited or diet-induced obesity), exenatide significantly enhances bone strength by increasing trabecular bone mass, bone formation and trabecular microarchitecture

The purpose of this review is to further elucidate the mechanism of action of GLP-1RAs in helping individuals with overweight or obesity to achieve and maintain weight loss

Genetically predicted glucose-dependent insulinotropic polypeptide (GIP) levels and cardiovascular disease risk are driven by distinct causal variants in the GIPR region

Bifidobacterium infantis produces acetate and lactate, two metabolites that serve as fuel for both Akkermansia muciniphila and Clostridium butyricum

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), which are widely used for the treatment of T2DM and promote weight loss in individuals with obesity, have demonstrated significant cardiovascular benefits